Compare TALK & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TALK | TBPH |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | 521 | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 788.5M | 824.9M |
| IPO Year | N/A | 2013 |
| Metric | TALK | TBPH |
|---|---|---|
| Price | $5.17 | $16.43 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $6.42 | ★ $17.80 |
| AVG Volume (30 Days) | ★ 7.9M | 559.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ 2.06 |
| Revenue | N/A | ★ $15,386,000.00 |
| Revenue This Year | $26.02 | $9.51 |
| Revenue Next Year | $21.24 | N/A |
| P/E Ratio | $155.55 | ★ $7.82 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.22 | $8.09 |
| 52 Week High | $5.20 | $21.03 |
| Indicator | TALK | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 64.20 | 57.81 |
| Support Level | $4.59 | $13.41 |
| Resistance Level | $5.19 | $19.04 |
| Average True Range (ATR) | 0.02 | 0.53 |
| MACD | -0.03 | 0.37 |
| Stochastic Oscillator | 56.25 | 95.82 |
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.